Anand Bagaria, senior research analyst, Finquest explains to CNBC-TV18 that pharma major Wockhardt has posted a strong run in terms of a stock performance as well as fundamentals and gained over 250% from the start of the year.
first published: Aug 7, 2012 03:22 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live
Will Rupee Slide & Expiry Day Caution Keep Nifty Bulls On The Back Foot? | Opening Bell Live
Sensex, Nifty Retreat After Hitting Fresh Highs As Rupee Drops To Record Low| Closing Bell Live
Will Solid Q2 GDP Set The Ball Rolling For Nifty Bulls To Cross 26,300 Decisively?|Opening Bell Live
